부산대학교 도서관

Background: Lung transplant recipients (LTRs) are at increased risk for coronavirus disease 2019 (COVID‐19)‐associated complications. Methods: We aimed to describe the outcomes of polymerase chain reaction‐documented severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in LTRs followed at our institution from March 2020 to July 2022. The primary outcome investigated was hospitalization or death from COVID‐19‐related symptoms within 28 days from diagnosis. Results: Overall, 60 cases were included, of which 18 (30%) reached the primary outcome. Only one patient (2%) died. Anti‐spike monoclonal antibodies (mAbs) were administered as early treatment in 36 patients (casirivimab/imdevimab = 2, sotrovimab = 31, and tixagevimab/cilgavimab = 3). Multivariate analysis revealed that age >60 years (p =.003; odds ratio [OR] 9.41; confidence interval [CI] 2.52–41.05) was associated with a higher risk for the primary outcome, while administration of mAbs as early treatment (p =.030; OR 0.23; CI 0.06–0.87) was associated with a lower risk. No effect of vaccination and SARS‐CoV‐2 variant was observed. Forced expiratory volume in 1 s and forced vital capacity values did not decrease among 37 patients who had spirometry performed 1 month after COVID‐19. Conclusions: We observed a relatively low morbidity and mortality of COVID‐19 in LTR. mAb administration was associated with a better outcome. [ABSTRACT FROM AUTHOR]